Accueil/Actions/SLS

SLS

USD

SELLAS Life Sciences Group Inc. Common Stock

$1.680-0.070 (-4.000%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$1.750

Haut

$1.770

Bas

$1.670

Volume

2.79M

Fondamentaux de l'Entreprise

Capitalisation Boursière

247.7M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

3.07M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $0.77Actuel $1.680Haut $2.48

Actualités Connexes

3 nov. 2025 · 14:00

GlobeNewswire

SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for

$SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting$